MyFinsight
Home
Blog
About
Proceeds from issuance of
shares, net of issuance...
$8,238K
(40.13%↑ Y/Y)
Net cash provided by
financing activities
$8,035K
(45.72%↑ Y/Y)
Canceled cashflow
$203K
Net change in cash
$4,926K
(4298.21%↑ Y/Y)
Canceled cashflow
$3,109K
Payments on short-term
financing arrangement
$155K
(-43.22%↓ Y/Y)
Repayments of notes payable
-$48K
(89.45%↑ Y/Y)
Stock-based compensation
$711K
(-59.00%↓ Y/Y)
Accounts payable,
accrued expenses and...
$623K
(656.25%↑ Y/Y)
Prepaid expenses and
other current assets
-$192K
(27.00%↑ Y/Y)
Change in fair value of
warrant liabilities
-$99K
(-223.75%↓ Y/Y)
Unrealized foreign
currency exchange gains
-$63K
(-115.99%↓ Y/Y)
Accretion of debt issuance
costs on convertible...
$10K
Net cash used in
operating activities
-$3,109K
(42.49%↑ Y/Y)
Canceled cashflow
$1,698K
Net loss
-$4,807K
(14.16%↑ Y/Y)
Back
Back
Cash Flow
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)
source: myfinsight.com